Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;29(12):2411-4.
doi: 10.1038/leu.2015.217. Epub 2015 Aug 10.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

J C Strefford  1 , L Kadalayil  2 , J Forster  1 , M J J Rose-Zerilli  1 , A Parker  3 , T T Lin  4 , N Heppel  4 , K Norris  4 , A Gardiner  3 , Z Davies  3 , D Gonzalez de Castro  5 , M Else  5 , A J Steele  1 , H Parker  1 , T Stankovic  6 , C Pepper  4 , C Fegan  4 , D Baird  4 , A Collins  2 , D Catovsky  5 , D G Oscier  1   3
Affiliations

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

J C Strefford et al. Leukemia. 2015 Dec.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1. Kaplan-Meier plots of mean telomere length (from MMQPCR) divided into three groups for PFS (A) and OS (B), and distribution of CLL biomarkers within the telomere length groups for 170 patients with complete data for TP53 and ATM status (C)
For (A) and (B), Log-rank P-value for each of the lower quartiles when compared to the Long group is <0.001. Long: >75 percentile; Intermediate: 50-75 percentile; Short: <50 percentile. The median PFS and OS for the 96 patients in the long TL group was 4.0 and 9.9 years respectively. This longer median survival was sustained when the analyses were performed with similarly categorised TL groups using measurements from both MMQPCR and STELA in the 111 patients with data for both (PFS: 8.1 and 5.1 years; OS: not reached and 9.8 years, Fig S5 and 6). For (C) data are presented in decreasing telomere length as measured by MMQPCR and divided into the three groups as described in the text. LONG: >75 percentile, INTERMEDIATE: 50-75 percentile, SHORT: <50 percentile. Each short vertical line (below the TL group name) corresponds to a patient. The presence and absence of each of the biomarker status listed on the left are represented by black and grey boxes respectively whereas white boxes indicate missing data on the biomarker status. *ZAP70 is expressed if >10%-positive cells by flow-cytometry, #CD38 is expressed if >7%-positive cells by flow-cytometry, Beta- M: beta-2 microglobulin (present: >4 mg/L), ¥Present: if: >3 deletions/changes per patient.
See this image and copyright information in PMC

References

    1. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116:1899–907. - PubMed
    1. Jones CH, Pepper C, Baird DM. Telomere dysfunction and its role in haematological cancer. Br J Haematol. 2012;156:573–87. - PubMed
    1. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia. Leukemia. 2009;23:1062–72. - PubMed
    1. Roos G, Kröber A, Grabowski P, Kienle D, Bühler A, Döhner H, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111:2246–52. - PubMed
    1. Mansouri L, Grabowski P, Degerman S, Svenson U, Gunnarsson R, Cahill N, et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients. Am J Hematol. 2013;88:647–51. - PubMed

Substances